CML: Asciminib Bests Standard TKIs as Frontline Therapy
Asciminib demonstrated efficacy vs standard-of-care frontline TKIs in newly diagnosed patients with CML.
Stay updated with breaking news from Financial Toxicity. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Asciminib demonstrated efficacy vs standard-of-care frontline TKIs in newly diagnosed patients with CML.
In Michigan, several efforts are underway to help cancer patients prepare for, manage, and alleviate the financial struggles associated with treatment.
The panelists provide perspectives on critical aspects of the CLL and SLL treatment landscape.
Medical experts provide their final thoughts regarding key treatment considerations for CLL and SLL.
MD Anderson's Ryan Huey, MD, offers a survey of research on a holistic approach to addressing financial toxicity during Patient Centered Oncology Care 2023.